4 December 2024
Trienix Pharma is proud to announce the appointment of
Dr. Charles Serhan to its Scientific Advisory Board

Dr. Serhan is a world-renowned pioneer in the field of specialized pro-resolving mediators (SPMs), whose seminal discoveries have redefined the biology of inflammation resolution and opened new therapeutic frontiers. He is the Simon Gelman Professor of Anaesthesia at Harvard Medical School and Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital. Dr. Serhan is also President and CEO of the International Eicosanoid Research Foundation, and has authored over 600 peer-reviewed publications, earning recognition among the world’s most cited scientists. His unparalleled expertise and leadership in translating SPM biology into innovative clinical applications will be instrumental in guiding Trienix Pharma’s R&D strategy, particularly in advancing our proprietary Protectin DX (PDX) analog platform toward transformative therapies in pain control, metabolic liver disease, and inflammation-driven disorders.